Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Nothing like a quick Brazil reset before the American Society of Clinical Oncology (ASCO) annual meeting Chicago rush.
Honored to Keynote at OncoNEXT Sao Paolo, Brazil on precision oncology + AI.
The panels and sharp Q/A from Brazil’s oncology community were next‑level. Feeling energized heading into ASCO 2026.
Thanks to all Brazilian colleagues for an amazing meeting experience.”
Other articles about ASCO on OncoDaily.
